NCT04662580

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2021-05-03Est. Completion: 2026-12-31

Enrollment target: 183 participants

Locations

UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California, Los Angeles School of Medicine, Los Angeles, California, United States
UCSF Medical Center at Mission Bay, San Francisco, California, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Washington University St. Louis School Medicine Siteman Cancer Center, St Louis, Missouri, United States
GU Research Network, Omaha, Nebraska, United States
Weill Cornell Medical College, New York, New York, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
University of Washington, Seattle, Washington, United States

Other microbiome trials you might be interested in

First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic CancerEARLY_PHASE1Recruiting

Metastatic Breast CancerMetastatic Prostate CancerGRPR-Targeted Molecular ImagingTheranostic RadiopharmaceuticalsCancerActive CancerTheranosticRadiopharmaceutical

This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performanc…

Perth, AustraliaEst. completion May 30, 2028

View Trial →

RegoNivo vs Standard of Care Chemotherapy in AGOCPhase 3Completed

Gastro-Oesophageal Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.